Literature DB >> 32166659

Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.

Hui Wei1, Hui-Liang Zhang1, Jia-Zhao Xie1, Dong-Li Meng1, Xiao-Chuan Wang1, Dan Ke2, Ji Zeng3, Rong Liu1.   

Abstract

Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase which participates in the regulation of multiple cellular processes. As a confirmed tumor suppressor, PP2A activity is downregulated in tumors and its re-activation can induce apoptosis of cancer cells. In the brains of Alzheimer's disease (AD) patients, decreased PP2A activity also plays a key role in promoting tau hyperphosphorylation and Aβ generation. In this review, we discussed compounds aiming at modulating PP2A activity in the treatment of cancer or AD. The upstream factors that inactivate PP2A in diseases have not been fully elucidated and further studies are needed. It will help for the refinement and development of novel and clinically tractable PP2A-targeted compounds or therapies for the treatment of tumor and AD.

Entities:  

Keywords:  Alzheimer’s disease; compounds; protein phosphatase 2A; tumor

Year:  2020        PMID： 32166659      PMCID： PMC7100444          DOI： 10.1007/s11596-020-2140-1

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN： 2523-899X


  104 in total

Review 1.  PP2A: the expected tumor suppressor.

Authors:  Veerle Janssens; Jozef Goris; Christine Van Hoof
Journal:  Curr Opin Genet Dev       Date:  2005-02       Impact factor: 5.578

Review 2.  Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.

Authors:  Jian-Zhi Wang; Yi-Yuan Xia; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains.

Authors:  S W Suh; K B Jensen; M S Jensen; D S Silva; P J Kesslak; G Danscher; C J Frederickson
Journal:  Brain Res       Date:  2000-01-10       Impact factor: 3.252

4.  Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease.

Authors:  Koichi Iijima; Anthony Gatt; Kanae Iijima-Ando
Journal:  Hum Mol Genet       Date:  2010-05-12       Impact factor: 6.150

5.  Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Authors:  Vincent Chung; Aaron S Mansfield; Fadi Braiteh; Donald Richards; Henry Durivage; Richard S Ungerleider; Francis Johnson; John S Kovach
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

6.  Progesterone decreases tyrosine hydroxylase phosphorylation state and increases protein phosphatase 2A activity in the stalk-median eminence on proestrous afternoon.

Authors:  Bin Liu; Lydia A Arbogast
Journal:  J Endocrinol       Date:  2009-11-27       Impact factor: 4.286

7.  CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Authors:  Ling-Ming Tseng; Chun-Yu Liu; Kung-Chi Chang; Pei-Yi Chu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2012-04-26       Impact factor: 6.466

8.  Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway.

Authors:  Xiaolong Yu; Xin Zhou; Changlin Fu; Qiang Wang; Tao Nie; Fan Zou; Runsheng Guo; Hucheng Liu; Bin Zhang; Min Dai
Journal:  Oncol Rep       Date:  2015-07-13       Impact factor: 3.906

9.  AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo.

Authors:  Manon Domise; Sébastien Didier; Claudia Marinangeli; Haitian Zhao; Pallavi Chandakkar; Luc Buée; Benoit Viollet; Peter Davies; Philippe Marambaud; Valérie Vingtdeux
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

10.  Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive Impairments.

Authors:  Yacoubou Abdoul Razak Mahaman; Fang Huang; Mengjuan Wu; Yuman Wang; Zhen Wei; Jian Bao; Maibouge Tanko Mahamane Salissou; Dan Ke; Qun Wang; Rong Liu; Jian-Zhi Wang; Bin Zhang; Dan Chen; Xiaochuan Wang
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472
View more
  5 in total

1.  Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease.

Authors:  Gyungah R Jun; Yang You; Congcong Zhu; Gaoyuan Meng; Jaeyoon Chung; Rebecca Panitch; Junming Hu; Weiming Xia; David A Bennett; Tatiana M Foroud; Li-San Wang; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Gerard D Schellenberg; Rhoda Au; Kathryn L Lunetta; Tsuneya Ikezu; Thor D Stein; Lindsay A Farrer
Journal:  Alzheimers Dement       Date:  2022-02-09       Impact factor: 16.655

Review 2.  Claims and reasons about mild COVID-19 in children.

Authors:  S Falahi; A Abdoli; A Kenarkoohi
Journal:  New Microbes New Infect       Date:  2021-03-17

3.  Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.

Authors:  Brunda Ganneru; Harsh Jogdand; Vijaya Kumar Daram; Dipankar Das; Narasimha Reddy Molugu; Sai D Prasad; Srinivas V Kannappa; Krishna M Ella; Rajaram Ravikrishnan; Amit Awasthi; Jomy Jose; Panduranga Rao; Deepak Kumar; Raches Ella; Priya Abraham; Pragya D Yadav; Gajanan N Sapkal; Anita Shete-Aich; Gururaj Desphande; Sreelekshmy Mohandas; Atanu Basu; Nivedita Gupta; Krishna Mohan Vadrevu
Journal:  iScience       Date:  2021-03-10

Review 4.  Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor.

Authors:  Na Liu; Rui Ling; Xiang Tang; Yunpeng Yu; Yuepeng Zhou; Deyu Chen
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

5.  Glimepiride mitigates tauopathy and neuroinflammation in P301S transgenic mice: role of AKT/GSK3β signaling.

Authors:  Mennatallah O Zaki; S El-Desouky; Doaa A Elsherbiny; Mohamed Salama; Samar S Azab
Journal:  Inflammopharmacology       Date:  2022-08-03       Impact factor: 5.093
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.